2024年意大利慢性乙型肝炎和丁型肝炎病毒确诊患者：基于全国真实世界数据库的估计
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database.
作者信息
Loglio Alessandro, Gardini Ivan, Conforti Massimiliano, Bartoli Marco, Silvia Francesco, Coppola Carmine, Chessa Luchino, Svegliati-Baroni Gianluca, Schiadà Laura, Gentile Ivan, Pinchera Biagio, Brunetto Maurizia Rossana, Colombatto Piero, Aghemo Alessio, De Nicola Stella, Toniutto Pierluigi, Giannini Edoardo Giovanni, Colecchia Antonio, Romagnoli Dante, Sarmati Loredana, Ponziani Francesca Romana, Morisco Filomena, Cammà Calogero, Cabibbo Giuseppe, Lampertico Pietro, Degasperi Elisabetta, Invernizzi Pietro, Ciaccio Antonio, Russo Francesco Paolo, Ippolito Antonio Massimo, Niro Grazia Anna, Terreni Natalia, Nardone Gerardo, Rocco Alba, D'Antò Maria, Sacerdoti David, Ieluzzi Donatella, Ciancio Alessia, Pellicelli Adriano, Federico Alessandro, Simone Loredana, Messina Vincenzo, Claar Ernesto, Rosato Valerio, D'Offizi Gianpiero, Caraceni Paolo, Muratori Paolo, Giaccherini Cinzia, Fagiuoli Stefano, Viganò Mauro
机构信息
Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy.
EpaC Ets, Italian Liver Patient Association, Monza, Italy.
出版信息
Liver Int. 2025 Oct;45(10):e70336. doi: 10.1111/liv.70336.
BACKGROUND AND AIMS
Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.
METHODS
The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 Regional Health Authorities. To understand how many CHB or CHD patients did not have these specific exemptions, a survey was conducted in 30 Gastroenterology, Hepatology and Infectious Diseases Units across the country.
RESULTS
Health Authorities data reported 67 514 and 5216 subjects with an exemption for CHB and for CHD, respectively. However, among 6775 CHB and 504 CHD patients, only 60.3% and 55.7% of them had the specific exemption, respectively. Based on these results, we estimated 111 960 (95% CI: 109 780-114 240) CHB and 9360 (95% CI: 8690-10 150) CHD patients, with a prevalence of 0.22% and 0.019% of the adult overall population. Moreover, anti-HDV prevalence was 7.7% from this cohort.
CONCLUSION
Our study provides a plausible estimate of the current number of adult patients diagnosed with CHB and CHD in Italy and may be considered the basis for decision-making health policies.
背景与目的
在过去几十年中，意大利的乙型肝炎（HBV）和丁型肝炎病毒（HDV）感染情况发生了显著变化，但缺乏可靠且最新的慢性乙型肝炎（CHB）和丁型肝炎（CHD）数据。本研究的目的是基于真实世界数据描述2024年意大利CHB和CHD的流行病学情况。
方法
从21个地区卫生当局获取了因CHB（016.070.32）和CHD（016.070.33）而享受医疗费用豁免的患者数量。为了解有多少CHB或CHD患者没有这些特定豁免，在全国30个胃肠病学、肝病学和传染病科室进行了一项调查。
结果
卫生当局数据报告显示，分别有67514名和5216名受试者因CHB和CHD获得豁免。然而，在6775名CHB患者和504名CHD患者中，分别只有60.3%和55.7%的人有特定豁免。基于这些结果，我们估计意大利有111960名（95%置信区间：109780 - 114240）CHB患者和9360名（95%置信区间：8690 - 10150）CHD患者，在成年总人口中的患病率分别为0.22%和0.019%。此外，该队列中抗HDV患病率为7.7%。
结论
我们的研究对意大利目前诊断为CHB和CHD的成年患者数量提供了合理估计，可被视为卫生政策决策的依据。
Zotero 插件